As per the terms of the agreement, Orexo is expected to take up the responsibly for supplying Abstral product to Invida.
However, Invida will be responsible for all regulatory, medical, marketing and sales activities in eleven countries across Asia Pacific, excluding China where the product is already partnered.
Financial terms of the agreement were not disclosed.
Invida president and CEO John Graham said this alliance will allow them to leverage their suite of capabilities to meet the growing demand for new, effective pain treatments in this region, and aligns with the goal of forging true partnerships, in which we are able to operate across the full value chain to bring pharmaceutical products into the Asia Pacific markets.